SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending downwards as investors react to the company's earnings report, which included a significant one-time tax charge and forecasts of increased capital expenditures for AI development. The community is debating whether this decline presents a buying opportunity or signals concerns about future profitability and spending discipline. Some believe the market is overreacting to a non-recurring event, while others worry about the long-term implications of Meta's aggressive AI investments.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Fueled by growing anticipation for its upcoming earnings report, GOOG is trending as the community discusses the potential impact of AI advancements and cloud services on its revenue. Positive sentiment is building around Google's core businesses, with some analysts raising price targets ahead of the report. Traders are also closely watching for updates on Google's AI strategy and partnerships, particularly regarding quantum computing.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending due to after-hours momentum and a low float, sparking community interest in a potential short squeeze. Discussions revolve around its potential to reach higher price levels, with some comparing it to other recent high-flying stocks. However, caution is advised as some traders are calling it a pump and dump scheme.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf ($WULF) is trending amid discussions of its recent $900M convertible note offering and its implications for dilution and growth, with community members debating the bullish and bearish interpretations of the financing structure. Bullish sentiment highlights the potential for expansion in AI and data centers, while bears focus on the risk of short-term price decline. The conversation also includes speculation around potential partnerships with major players like Google.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending after a surprise Q3 profit and upgraded guidance sparked bullish sentiment among retail traders. The community is focused on a potential short squeeze, with some anticipating a re-rating of the stock. Optimism is fueled by discussions of debt repayment, potential buyouts, and the company's future revenue prospects.

Vanguard Group, Inc. - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is trending due to a mix of political and economic factors, including discussions around Trump's policies and their impact on various sectors. Community members are debating the potential effects of tariffs, trade deals, and government actions on market stability and individual companies. There's also active discussion about the Federal Reserve's interest rate decisions and their implications for future economic growth.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle's stock is trending downwards after disappointing earnings and lowered guidance, with concerns about declining customer traffic and macroeconomic pressures. The community is discussing whether the stock is oversold and if a significant bounce is likely. Many express concerns about high prices, reduced portion sizes, and declining food quality impacting the brand's popularity.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors anticipate upcoming earnings, with expectations high for the tech giant's AI and cloud performance; the stock has already seen significant gains, leading to discussions about whether the positive outlook is fully priced in. Community members are also reacting to news of partnerships, including collaborations to power AI infrastructure.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI is trending as the 'Bitcoin of memes,' sparking excitement about its potential within the crypto space; the community rallies behind the narrative that 'We are all Satoshi.' Anticipation is building for upcoming events that could further propel the token's visibility and adoption.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust Series 1 (QQQ) is trending amid discussions around potential trade deal implications after recent communications between global leaders. The market is analyzing the potential impacts of these discussions on sectors heavily represented in the fund, particularly technology. Community sentiment appears cautiously optimistic, yet acknowledges that previous similar announcements have not led to substantial long-term gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Purple said that it has achieved a commercially viable yield for IM1240, positioning the program competitively for future development.</li><li>The company now plans to make an Investigational New Drug (IND) submission to the U.S. Food and Drug Administration in 2026, paving the way for its first-in-human clinical trials. &nbsp;</li></ul>NASDAQ-listed shares of Purple Biotech Ltd. (PPBT) soared 92% on Wednesday morning after the company achieved a manufacturing milestone for its experimental cancer drug IM1240.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/29/3176325/0/en/Purple-Biotech-Achieves-Manufacturing-Milestone-for-IM1240-a-Tri-Specific-Antibody-from-the-CAPTN-3-Platform.html">said</a> that it has achieved a commercially viable yield for IM1240, positioning the program competitively for future development.IM1240 is a tri-specific antibody from the CAPTN-3 preclinical platform targeting the antigen 5T4, which is expressed in a variety of solid tumors and is associated with advanced disease, increased invasiveness, and poor clinical outcomes. The company now plans to make an Investigational New Drug (IND) submission to the U.S. Food and Drug Administration in 2026, paving the way for its first-in-human clinical trials.<blockquote>“Drawing on my decades of experience in antibody manufacturing, producing a tri-specific protein such as IM1240 at high yield and purity was perceived as a significant challenge-one that I’m pleased to have successfully mastered.”&nbsp; Michael Schickler, Head of Clinical and Regulatory Affairs, Purple Biotech</blockquote><h2 class="st-heading-2">Window To Maintain Listing Standards&nbsp;</h2>Earlier this month, Purple Biotech received a letter from the Nasdaq, notifying the company that it is not in compliance with the minimum bid price requirement for continued listing on the bourse.&nbsp;The company now has until April 14, 2026, to regain compliance with the minimum bid price requirement.<h2 class="st-heading-2">What Is Retail Thinking?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PPBT">PPBT stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.A Stocktwits user now expects a dilution, provided the company needs money.<stembedurl>https://stocktwits.com/Stocksavior14/message/634120144</stembedurl>Another, however, believes that the stock will yield real profits in time.<stembedurl>https://stocktwits.com/McTradesPharmD_MBA/message/634121569</stembedurl>PPBT stock is down by 76% this year and by about 68% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-partners-with-walmart-to-expand-access-to-popular-weight-loss-drug/cLGZNj7R3wE">Eli Lilly Partners With Walmart To Expand Access To Popular Weight-loss Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Purple Biotech Shares Soar 92% On Breakthrough For Experimental Cancer Drug

Purple said that it has achieved a commercially viable yield for IM1240, positioning the program competitively for future development.

Equity

Shares of Purple Biotech closed down 3.4% on Monday and extended losses in after-hours trading as the company's latest financial results failed to impress the broader market, though retail traders showed some optimism.The company reported a net loss of $0.4 million for the fourth quarter of 2024, significantly narrowing from the $4.9 million loss in the same period a year earlier, primarily due to lower research and development (R&amp;D) expenses.&nbsp;Loss per American depository share (ADS) was $0.20 (basic) and $0.26 (diluted), compared to $3.80 per ADS in Q4 2023, and better than LSEG's mean analyst estimate of a loss of $1.80.CEO Gil Efron highlighted key 2024 milestones, including successful trials for its clinical-stage programs for its cancer therapy candidates <a href="https://stocktwits.com/news-articles/markets/equity/ppbt-stock-surges-on-cancer-drug-cm24-results/cJ9kF29Rh2">CM24</a> and NT219 and advancements in its CAPTN-3 tri-specific platform.&nbsp;The randomized Phase 2 trial for CM24 in second-line pancreatic cancer met all efficacy endpoints, and biomarker data informed a planned Phase 2b study for the second half of 2025.&nbsp;Meanwhile, NT219's dose escalation study determined a recommended Phase 2 dose, enabling a head and neck cancer trial in collaboration with the University of Colorado, expected to begin enrollment in early 2025.Retail sentiment on Stocktwits ended on a bullish note on Monday, but the score was slightly lower than a day ago.&nbsp;<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/PPBT_sentiment_and_message_volume_as_of_March_10_03a40ad961.png" alt="PPBT sentiment and message volume as of March 10.png" width="1316" height="302"><figcaption>PPBT sentiment and message volume as of March 10. | source: Stocktwits</figcaption></figure>Some traders pointed to Purple Biotech's cash runway as a positive factor and speculated that institutional investors may disclose their positions in upcoming 13-F filings, given the strong stock-buying volume observed this year.&nbsp;<stembedurl>https://stocktwits.com/Smittysixty/message/607496322</stembedurl>However, skepticism also lingered. One user questioned the absence of a clear regulatory path for the company's drug candidates, arguing that cost-cutting measures were meaningless without a concrete FDA approval strategy.&nbsp;<stembedurl>https://stocktwits.com/Duediligence20/message/607503439</stembedurl>Others accused management of raising capital to "milk it for salaries."As of Dec. 31, 2024, Purple Biotech had $8.2 million in cash and short-term deposits, which it expects will be sufficient to fund operations into mid-2026.&nbsp;In Q4, the company raised $2.8 million through a registered direct offering and an additional $1.5 million via an open-market sale of 298,000 ADSs at an average price of $3.50.<a href="https://stocktwits.com/symbol/PPBT">Purple Biotech's stock</a> has lost over 45% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Purple Biotech's Shrinking Losses Keep Retail Sentiment In The Green, But Other Pressures Loom

As of Dec. 31, 2024, Purple Biotech had $8.2 million in cash and short-term deposits, which it expects will be sufficient to fund operations into mid-2026.

WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters.&nbsp;Our focus is on quality, liquid, growth-oriented, and under-followed companies in sectors actively drawing in capital such as AI, blockchain, biotech and consumer.&nbsp;This real-time news surveillance and targeting combined with our proprietary 5-point analysis, aids in uncovering stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.&nbsp;Here’s what we’re keeping our eyes on:<h3>1. Purple Biotech (NASDAQ: PPBT)</h3>Background: Purple Biotech is a clinical-stage oncology company that aims to redefine cancer treatment through its innovative approaches targeting tumor immune evasion and drug resistance. Its lead product, CM24, is a first-in-class anti-CEACAM1 antibody being developed to treat pancreatic and other aggressive cancers. The oncology space, worth billions, continues to see intense investor interest, especially as companies explore biomarker-driven therapies.The News: Purple Biotech unveiled final Phase 2 results showing CM24 combined with nivolumab and chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) in pancreatic cancer patients with specific biomarkers. The data revealed a 79% reduction in death risk and a 5.1-month OS improvement, particularly in biomarker-enriched patient groups.What It Means: These results not only validate CM24’s potential but also position Purple Biotech to expand its pipeline into broader cancer applications. With a planned Phase 2b trial targeting high-CEACAM1 patients, the company is tapping into precision oncology—a sector that continues to draw investor enthusiasm due to its game-changing potential.Stock Reaction: PPBT skyrocketed 151%, reflecting the market’s recognition of this major milestone in the fight against pancreatic cancer.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_23_40_AM_19763a2e26.png" alt="Screenshot 2024-12-05 at 2.23.40 AM.png">&nbsp;<hr>&nbsp;<h3>2. Stereotaxis (NYSE: STXS)</h3>Background: Stereotaxis is at the forefront of surgical robotics, specializing in robotic magnetic navigation (RMN) systems for minimally invasive endovascular interventions. Its GenesisX system aims to improve precision, safety, and efficiency in procedures, a critical innovation as the global market for robotic-assisted surgeries is projected to grow at a double-digit CAGR over the next decade.The News: The GenesisX robotic system was showcased for the first time at the RSNA 2024 Annual Meeting, in collaboration with Neusoft Medical Systems. The partnership aligns GenesisX with advanced imaging technologies, offering enhanced capabilities for healthcare providers worldwide.What It Means: The exposure at RSNA, one of the largest radiology conferences globally, strengthens Stereotaxis' visibility and positions the GenesisX as a next-generation tool for minimally invasive surgeries. This partnership could unlock new revenue streams as the healthcare sector increasingly adopts robotic solutions.Stock Reaction: STXS edged up 4.18%, with investors optimistic about the long-term implications of the GenesisX system.Stocktwits.com Sentiment &amp; Popularity:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_25_09_AM_6fecf5b145.png" alt="Screenshot 2024-12-05 at 2.25.09 AM.png">&nbsp;<hr>&nbsp;<h3>3. Delcath Systems (NASDAQ: DCTH)</h3>Background: Delcath Systems focuses on innovative therapies for primary and metastatic liver cancers. Its flagship product, HEPZATO KIT™, offers a unique approach to delivering high-dose chemotherapy directly to the liver while minimizing systemic exposure. This precision is critical for targeting liver-dominant diseases—a market that represents tens of thousands of patients annually.The News: The FDA has cleared Delcath’s Phase 2 trial of HEPZATO in liver-dominant metastatic colorectal cancer. The study will compare HEPZATO plus standard chemotherapy with chemotherapy alone, aiming to validate its safety and efficacy in this high-need population.What It Means: HEPZATO has already shown promise in metastatic uveal melanoma, and this expansion could significantly broaden its market reach. The ability to address liver-dominant cancers positions Delcath as a potential leader in a niche but high-value market.Stock Reaction: DCTH rose 6.4% on the day, continuing its strong performance following a 203% year-to-date rally.&nbsp;&nbsp;<hr>&nbsp;<h3>4. BrainStorm Cell Therapeutics (NASDAQ: BCLI)</h3>Background: BrainStorm is a pioneering biotech company developing autologous adult stem cell therapies for neurodegenerative diseases like ALS and progressive MS. Its lead candidate, NurOwn®, is designed to deliver neurotrophic factors directly to damaged neurons, potentially altering the course of these debilitating diseases. With few effective therapies for ALS, the market is ripe for disruptive innovation.The News: BrainStorm announced a December 11 webinar featuring updates on its Phase 3b trial of NurOwn, aimed at refining the therapy’s efficacy for FDA approval. This comes as the company prepares for a pivotal registrational trial.What It Means: If successful, NurOwn could be the first significant breakthrough for ALS in years, addressing an unmet medical need in a multibillion-dollar market. The company’s focus on early-stage ALS patients may improve trial outcomes and strengthen its case for regulatory approval.Stock Reaction: BCLI dipped 2.66%, reflecting cautious investor sentiment as the market awaits trial data.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_26_15_AM_28681ca8de.png" alt="Screenshot 2024-12-05 at 2.26.15 AM.png">&nbsp;<hr>&nbsp;<h3>5. DMG Blockchain Solutions (OTCQB: DMGGF)</h3>Background: DMG Blockchain integrates Bitcoin mining with sustainability and AI-driven data centers. Its Terra Pool initiative is designed to create a carbon-neutral Bitcoin mining ecosystem, catering to ESG-conscious investors and industries. With institutional adoption of Bitcoin accelerating, DMG’s dual focus on growth and environmental responsibility makes it a standout.The News: DMG reported November mining results of 32 BTC, an increased hashrate of 1.66 EH/s, and significant insider purchases by its CEO and COO. The company also secured $17.3 million to fund growth initiatives, including AI and blockchain infrastructure.What It Means: The raised capital and insider purchases signal confidence in DMG’s ability to scale operations and align with Bitcoin’s anticipated market growth. The focus on sustainability could attract institutional players prioritizing ESG compliance.Stock Reaction: DMGI remained stable dipping just slightly, with the market digesting the long-term growth potential from recent investments.&nbsp;<hr>&nbsp;<h3>6. BriaCell Therapeutics (NASDAQ: BCTX)</h3>Background: BriaCell specializes in novel immunotherapies targeting advanced breast cancer. Its lead therapy, Bria-IMT™, is designed to boost the immune system's response against tumors. With metastatic breast cancer affecting over 2 million women globally, there’s an urgent need for effective treatments.The News: BriaCell’s pivotal Phase 3 study of Bria-IMT received a positive safety review from the DSMB, allowing the trial to proceed without changes. The trial is being conducted under the FDA’s Fast Track Designation.What It Means: The DSMB’s approval reinforces Bria-IMT’s safety and paves the way for the company to potentially deliver a game-changing therapy for metastatic breast cancer patients. The Fast Track Designation further emphasizes its potential impact.Stock Reaction: BCTX shares soared 13%, reflecting growing investor confidence in the company’s clinical progress.Rumours from Twitter:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_27_31_AM_e685b0a306.png" alt="Screenshot 2024-12-05 at 2.27.31 AM.png">&nbsp;&nbsp;<h3>7. Laser Photonics Corporation (NASDAQ: LASE)</h3>Background: Laser Photonics Corporation specializes in industrial laser systems, providing innovative solutions for cleaning, material processing, and now pharmaceuticals. With its recent acquisition of Control Micro Systems, Inc., the company is expanding into new sectors, including the fast-growing pharmaceutical and semiconductor industries. The industrial laser market, driven by advances in automation and precision engineering, is projected to exceed $10 billion by 2030, making it a hotbed for innovation.The News: Laser Photonics announced the successful installation of a state-of-the-art pill drilling system at a customer’s facility. The system, a Class I automated CO2 laser with advanced fume extraction and machine vision inspection, is designed to streamline pill production processes. This system also doubles as an anti-counterfeiting solution, addressing critical challenges in the pharmaceutical supply chain.What It Means: This installation signifies Laser Photonics’ pivot into high-demand verticals like pharmaceuticals. By integrating advanced laser technology with automated inspection, the company is positioning itself as a key supplier in a market prioritizing efficiency, precision, and security.Stock Reaction: LASE shares declined 6.40%, reflecting broader market volatility rather than company-specific concerns. Investors appear cautiously optimistic about the company's potential in its newly targeted markets.&nbsp;Also Read:<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/why-this-small-biotech-stock-could-be-primed-for-a-breakout/">&nbsp;Why This Small Biotech Stock Could Be Primed for a Breakout</a>Be the First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like&nbsp;AST SpaceMobile (NASDAQ: ASTS), which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a long or short position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Yesterday’s Hottest News That Could Move the Needle Today

Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks

<a href="https://stocktwits.com/symbol/PPBT">Shares of Purple Biotech</a> (PPBT) surged more than 45% on Monday morning, reaching their highest levels since early October.&nbsp;The Israel-based biopharma reported positive final results from a randomized Phase 2 study of its lead oncology drug, CM24, in patients with pancreatic ductal adenocarcinoma (PDAC).“We are very excited about the final data, demonstrating CM24’s clear and consistent improvement across all efficacy endpoints evaluated in our randomized Phase 2 study,” stated Purple Biotech CEO Gil Efron.&nbsp;He added that the enhanced results in patients with CEACAM1 and other serum markers gave them optimism that selecting a biomarker-enriched patient population could further increase CM24’s efficacy, potentially positioning it as a treatment for multiple CEACAM1-expressing malignancies.The Phase 2 study evaluated CM24, a novel first-in-class anti-CEACAM1 antibody, in combination with Bristol Myers Squibb’s immune checkpoint inhibitor nivolumab and standard-of-care chemotherapy in second-line metastatic PDAC patients. This was compared to chemotherapy alone.<figure class="image"><a href="https://stocktwits.com/symbol/PPBT"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/PPBT_sentiment_and_message_volume_9a32199173.png" alt="PPBT sentiment and message volume.png" width="1314" height="320"></a><figcaption>PPBT sentiment and message volume on Dec 2 as of 10:00 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for PPBT soared to an ‘extremely bullish’ (93/100) score, up from ‘neutral’ just a day ago, accompanied by a surge in message volume.&nbsp;One user optimistically said that PPBT should be trading at $250 per share, 50 times its current price, while another referred to CM24 as “the only pancreatic cancer drug.”<stembedurl>https://stocktwits.com/Duediligence20/message/594680510</stembedurl><stembedurl>https://stocktwits.com/Jpurpleteam/message/594672273</stembedurl>CM24 targets CEACAM1, a multi-functional membrane glycoprotein that plays a critical role in tumor invasiveness, metastasis, and immune evasion.&nbsp;The drug also affects serum neutrophil extracellular trap (NET) levels, which are involved in trapping and neutralizing pathogens.Still, PPBT stock has dropped more than 65% year-to-date.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-li-xpev-stocks-in-focus-after-record-november/cJ9kNexRhT">Nio, Li Auto, Xpeng Stocks In Focus After China EV Makers Set Monthly Record Deliveries In November</a>

The Israel-based biopharma reported positive final results from a randomized Phase 2 study of its lead oncology drug, CM24, in patients with pancreatic ductal adenocarcinoma.

Purple Biotech Stock Hits Nearly 2-Month High On Cancer Drug Trial Success: Retail Thrilled

CM24 targets CEACAM1, a multi-functional membrane glycoprotein that plays a critical role in tumor invasiveness, metastasis, and immune evasion.

Purple Biotech Reveals Promising CM24 Study Results

Purple Biotech (PPBT) has released an update. Purple Biotech has announced encouraging interim results from their Phase 2 study of CM24 for pancrea...

Purple Biotech Eyes Key 2024 Milestones

Purple Biotech (PPBT) has released an update. Purple Biotech, listed as PPBT on NASDAQ/TASE, has entered a robust phase with multiple clinical data...

Why Purple Biotech (PPBT) Shares Are Trading Lower

Purple Biotech shares are trading lower by 11.5% during Monday's session. The company announced the exercise of warrants for $2 million gross proceeds.
read more...

Purple Biotech (NASDAQ:PPBT) Trading 9.7% Higher

Purple Biotech Ltd. (NASDAQ:PPBT - Get Free Report)'s share price was up 9.7% during trading on Thursday . The company traded as high as $0.67 and last traded at $0.67. Approximately 98,128 shares...

Purple Biotech reports Q4 EPS (19c), consensus (19c)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Purple Biotech convenes a head, neck cancer SAB ahead of NT219 trial

Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The oncology pipeline includes CM24, NT219, and CAPTN-3. The CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. The NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.

Purple Biotech Ltd - ADR

Will Apple (AAPL) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$1.06
Prev Close	$0.583
Open	$1.07
Dividend Yield	0.00%
50-Day Moving Average	$0.8966
Beta	0.51
Avg. Volume	2.86M
PE Ratio	-0.95

52-Week High	$13.95
52-Week Low	$0.5326
Market Capitalization	$19.88M
EPS (Annual)	-$2.80
Price to Book	0.09
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

PPBT
Purple Biotech Ltd - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest PPBT News

PPBTPurple Biotech Ltd - ADR